Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469573 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes
A Phase 4 study, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT00469573: Completed Phase 4 study, sponsored by Innovative Medical.
NCT00469573 is a Phase 4 study that has completed, run by Innovative Medical. The registered enrollment target is 36 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00469573, a Phase 4 study, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Optive®eye drops are safe for people who wear contact lenses and have dry eyes. The second goal of the study is to determine if using Optive®eye drops can improve my dry eye scores on a standard dry eye test (called the OSDI).
Interventions
- DRUG 1. Optive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-03 |
| Phase | Phase 4 |
What the finished NCT00469573 record still lists
NCT00469573 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which 1. Optive is the first listed.
NCT00469573 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00469573 about?
NCT00469573 is a clinical study titled "Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes". The purpose of this study is to determine if Optive®eye drops are safe for people who wear contact lenses and have dry eyes. The second goal of the study is to determine if using Optive®eye drops can improve my dry eye scores on a standard dry eye test (called the OSDI).
What is the current status of trial NCT00469573?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2007-05. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00469573?
The interventions under investigation include: 1. Optive (DRUG).
Who is sponsoring clinical trial NCT00469573?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00469573's enrollment target sits among peer trials
36 1490th of 2000 higher than 495 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia